Although T cell activation is associated with disease progression in untreated human immunodeficiency virus type 1 (HIV-1) infection, its significance in antiretroviral-treated patients is unknown. Activated (CD38 + HLA-DR + ) T cell counts were measured in 99 HIV-infected adults who had maintained a plasma HIV RNA level р1000 copies/mL for a median of 21 months while receiving antiretroviral therapy. Patients with sustained viral suppression had lower levels of T cell activation than untreated patients but higher levels than HIVuninfected control subjects. Persistent T cell activation was associated with decreased CD4 + T cell gains during therapy. For every 5% increase in the proportion of activated CD8 + T cells, 35 fewer CD4 + T cells/mm 3 were gained. Increased T cell activation was associated with shorter duration of viral suppression, hepatitis C virus coinfection, frequent low-level viremia, and lower nadir CD4 + T cell counts. Interventions that directly target T cell activation or the determinants of activation may prove to be useful adjuvants to antiretroviral therapy.
Although T cell activation is associated with disease progression in untreated human immunodeficiency virus type 1 (HIV-1) infection, its significance in antiretroviral-treated patients is unknown. Activated (CD38
+ HLA-DR + ) T cell counts were measured in 99 HIV-infected adults who had maintained a plasma HIV RNA level р1000 copies/mL for a median of 21 months while receiving antiretroviral therapy. Patients with sustained viral suppression had lower levels of T cell activation than untreated patients but higher levels than HIVuninfected control subjects. Persistent T cell activation was associated with decreased CD4 + T cell gains during therapy. For every 5% increase in the proportion of activated CD8 + T cells, 35 fewer CD4 + T cells/mm 3 were gained. Increased T cell activation was associated with shorter duration of viral suppression, hepatitis C virus coinfection, frequent low-level viremia, and lower nadir CD4 + T cell counts. Interventions that directly target T cell activation or the determinants of activation may prove to be useful adjuvants to antiretroviral therapy.
Despite clear improvements in morbidity and mortality that are associated with the use of highly active antiretroviral therapy (HAART) [1, 2] , human immunodeficiency virus type 1 (HIV-1)-infected patients often do not have normal CD4
ϩ T cell counts, even after several years of sustained suppression of plasma HIV RNA levels [3, 4] . Furthermore, although most patients experience CD4 ϩ T cell gains while receiving HAART, some experience a plateau in CD4 ϩ T cell gains shortly after initiation of therapy [5] . Differences in thymic function likely explain some of this variability in im-HIV infection, levels of T cell activation are generally high [13] , which results in rapid proliferation and apoptosis [14] [15] [16] [17] , enhanced CD4 ϩ T cell susceptibility to infection [18] [19] [20] [21] [22] , and enhanced HIV replication in infected cells [23] [24] [25] . T cell activation is thought by many to be the proximate cause of CD4 ϩ T cell depletion in untreated patients [26] [27] [28] [29] [30] . Although less is known about T cell activation among patients treated with HAART, abnormal levels of T cell activation may persist even after 3 years of sustained viral suppression [4] .
To address the question of whether persistent T cell activation affects immune reconstitution in HIV-infected patients with viral suppression during HAART, we identified patients who had maintained viral suppression for у3 months, measured activated T cell subsets by flow cytometry, and assessed the relationship between T cell activation and the overall CD4 ϩ T cell changes experienced during HAART. We also evaluated factors associated with T cell activation.
SUBJECTS AND METHODS
Participants. Participants were selected from the Study of the Consequences of the Protease Inhibitor Era (SCOPE), a clinic-based cohort of 450 chronically HIV-infected patients who receive primary care in HIV/AIDS specialty clinics at either San Francisco General Hospital or the San Francisco Veterans Affairs Medical Center. The cohort was assembled to represent distinct groups of HIV-infected persons: 25% of participants were untreated at enrollment; 50% were receiving HAART but were in a state of virologic failure at enrollment, with plasma HIV RNA levels consistently 11000 copies/mL for at least 24 weeks; and 25% were receiving HAART at enrollment and had been experiencing virologic suppression with plasma HIV RNA levels consistently !50 copies/mL for at least 24 weeks, with allowance for occasional transient detectable viremia р1000 copies/mL. Participants are seen at 4-month intervals, at which times a detailed questionnaire that collects information about antiretroviral use and risk behavior is administered and blood and saliva specimens are obtained. The first 175 consecutive SCOPE participants had immunophenotyping of T cells performed at the second study visit. Participants were included in the present analysis if they were receiving HAART, had a plasma HIV RNA level р1000 copies/mL on the day of immunophenotyping and for at least 3 months before immunophenotyping, and had a documented CD4 ϩ T cell count determination within 6 months before the initiation of HAART. We included participants with plasma HIV RNA levels that were detectable (50-1000 copies/mL), because intermittent episodes of low-level viremia are commonly observed in patients who have durable viral suppression [31] , and such events generally do not result in treatment modification [32, 33] ; in addition, we were interested in examining the relationship between lowlevel viremia and T cell activation. Patients were not excluded for intercurrent illnesses or immunizations. HAART was defined as a regimen of у3 antiretroviral drugs that included a protease inhibitor, a nonnucleoside reverse-transcriptase inhibitor, or abacavir. Saquinavir hard gel capsule-based regimens were considered to be HAART only if they were combined with ritonavir. Thirteen untreated HIV-infected participants and 6 healthy HIV-uninfected volunteers were also included, as comparison groups.
Measurements. Information about demographic characteristics and antiretroviral medication use at the time of and after SCOPE enrollment was collected by structured interview; medication use before cohort enrollment was determined by medical chart abstraction. Plasma HIV RNA levels were determined by the bDNA amplification technique (Quantiplex HIV RNA; Chiron), either during the course of clinical care, before entry into the cohort (versions 2.0 and 3.0), or at every 4-month study-related visit (all version 3.0). Hepatitis C virus serostatus was determined by Abbott Hepatitis C Virus Enzyme Immunoassay version 2.0 (Abbott Laboratories). CD4
ϩ T cell counts were measured by the clinical laboratories associated with each medical center. Pretherapy CD4 ϩ T cell counts and plasma HIV RNA levels were defined as the last available measurement before initiation of HAART. The nadir CD4 ϩ T cell count was the lowest confirmed value before initiation of HAART.
Immunophenotyping was performed using freshly collected, EDTA-anticoagulated whole blood and analyzed by 4- The date of viral suppression was defined as the midpoint between the date of the last plasma HIV RNA level 11000 copies/mL measured during HAART (or the date of HAART initiation, if there were no plasma HIV RNA levels 11000 copies/mL during HAART) and the date on which the first subsequent plasma HIV RNA level р1000 copies/mL was measured. If a participant achieved viral suppression and then had a plasma HIV RNA level 11000 copies/mL, the date of viral suppression was determined after the last measurement of a plasma HIV RNA level 11000 copies/mL. The duration of viral suppression was defined as the time interval between the date on which viral suppression was achieved and the date of flow cytometry. The overall frequency of low-level viremia during virologically suppressive HAART was defined as the percentage of all plasma HIV RNA measurements made after the date of viral suppression up to and including the date of immunophenotyping that were detectable (50-1000 copies/mL). The frequency of low-level viremia in the year before immunophenotyping was defined as the percentage of all plasma HIV RNA measurements in the year before immunophenotyping and after the date of viral suppression that were detectable (50-1000 copies/mL).
Because the early gains in peripheral CD4 ϩ T cell counts that occur after initiation of HAART are largely the result of redistribution from lymphoid tissue [34] [35] [36] , we analyzed separately the factors associated with early and late CD4 ϩ T cell count changes during HAART. For each participant, the early change in CD4 ϩ T cell count was calculated by subtracting the pretherapy CD4 ϩ T cell count from the CD4 ϩ T cell count at month 3 of HAART (median count within a 10-week window). The late change in CD4 ϩ T cell count was calculated by subtracting the CD4 ϩ T cell count at month 3 of HAART from the CD4 ϩ T cell count at the time of immunophenotyping (median count within a 3-month window). For participants in whom viral suppression occurred after month 3 of HAART, the late CD4 ϩ T cell changes were calculated by subtracting the CD4 ϩ T cell count at the date of viral suppression (median count within a 3-month window) from the CD4 ϩ T cell count at the time of immunophenotyping. Factors associated with early and late HAART-mediated CD4 ϩ T cell count changes were analyzed using linear regression. Percentages of activated CD4 ϩ and CD8 ϩ T cells, age, sex, pretherapy CD4 ϩ T cell count, log 10 pretherapy plasma HIV RNA level, and hepatitis C virus serostatus were all considered to be potentially associated with early CD4 ϩ T cell count changes. In addition to each of these factors, the percentage of naive CD4 ϩ T cells, the time maintaining viral suppression, and the frequency of low-level viremia were considered to be potentially associated with late CD4 ϩ T cell count changes. All factors considered were included in a single multivariable model. In these analyses and all subsequent regression analyses, model residuals were evaluated to assess their conformity with the assumptions of linear regression. Factors associated with CD4 ϩ and CD8 ϩ T cell activation among patients with HAART-mediated viral suppression were also assessed using linear regression. The duration of viral suppression, hepatitis C virus serostatus, the frequency of low-level viremia in the year before immunophenotyping, and the nadir CD4 ϩ T cell count were all considered to be potentially associated with both CD4 ϩ and CD8 ϩ T cell activation. The frequency of low-level viremia in the year before immunophenotyping was categorized in modeling both CD4 ϩ and CD8 ϩ activation markers to meet the model assumptions. All factors considered were included in a single multivariable model. All analyses were performed with STATA version 7.0.
RESULTS

Baseline characteristics.
A total of 99 HAART-treated participants who had maintained plasma HIV RNA levels р1000 copies/mL for at least 3 months before immunophenotyping were included in the analysis. The majority were men between the ages of 40 and 50 years who were receiving a protease inhibitor-based HAART regimen ( 3 ); 28% of participants were coinfected with hepatitis C virus; and the median duration of viral suppression was 21 months (IQR, 11-36 months). The median frequency of plasma HIV RNA measurements that were detectable (50-1000 copies/mL) was 20% (IQR, 5%-44%).
Abnormal levels of T cell activation despite HAART-mediated viral suppression. After a median of 21 months of viral suppression, the HAART-treated patients had a lower median percentage of activated (CD38 ϩ HLA-DR ϩ ) CD4 ϩ T cells (4%; IQR, 3%-7%) than untreated HIV-infected participants (8%; IQR, 7%-15%; ) but a higher median percentage P ! .001 than HIV-uninfected volunteers (1%; IQR, 1%-2%; ) P ! .001 ( figure 1A) . Similarly, the HAART-treated patients had a lower median percentage of activated CD8 ϩ T cells (11%; IQR, 7%-18%) than untreated HIV-infected participants (46%; IQR, 31%-51%; ) but a higher percentage than HIV-unin-P ! .001 fected volunteers (1%; IQR, 1%-3%; ) (figure 1B). Par-P ! .001 ticipants with HAART-mediated viral suppression continued to have higher levels of both CD4 ϩ and CD8 ϩ T cell activation than the HIV-uninfected control subjects, even when the analysis was restricted to the 58 participants who had negative results of serologic testing for hepatitis C virus or the 68 participants who had maintained undetectable plasma HIV RNA levels in the year before immunophenotyping ( for all P ! .001 comparisons). 
Association between CD4 + T cell activation and blunted early CD4
+ T cell gains. The median early CD4 ϩ T cell count change-between the last measurement before the initiation of HAART and month 3 of HAART-was ϩ53 cells/mm 3 (IQR, ϩ3 to ϩ114 cells/mm 3 ). Although the extent of CD4 ϩ T cell activation was measured, on average, 2 years later, it was found to be associated with these early changes in CD4 ϩ T cell count.
After adjustment for other factors, for every 5% increase in the proportion of activated CD4 ϩ T cells, 45 fewer CD4 ϩ T cells/ mm 3 were gained between the measurement before initiation of HAART and that at month 3 after initiation of HAART ( ). Although each 1 log 10 increase in the pretherapy P p .02 plasma HIV RNA level was associated with an increase of 29 CD4
ϩ T cells/mm 3 in the gain that occurred during the first 3 months in an unadjusted analysis ( ), only a trend P p .006 toward higher early CD4 ϩ T cell gains was seen in association with higher pretherapy plasma HIV RNA levels (ϩ23 cells/mm 3 for each increase of 1 log 10 copy/mL) after adjustment for the extent of CD4 ϩ T cell activation among other factors (P p Factors associated with T cell activation during antiretroviral treatment. We next evaluated factors associated with T cell activation among the 99 patients who had sustained viral suppression while receiving HAART. Levels of CD4 ϩ and CD8 ϩ T cell activation were highly correlated ( , Spearman's r p 0.67 correlation coefficient;
). There was also a clear rela-P ! .001 tionship between both CD4 ϩ and CD8 ϩ T cell activation and duration of viral suppression. Markers of CD4 ϩ and CD8 ϩ T cell activation appear to decrease as duration of viral suppression increases (figure 2). After adjustment for the frequency of low-level viremia in the year before immunophenotyping, among other factors, for every month of viral suppression, there were 0.06% fewer activated CD4 ϩ T cells ( ) and 0.1% P p .03 fewer activated CD8 ϩ T cells ( ) (table 3) . Participants P p .04 coinfected with hepatitis C virus had 2% more activated CD4 ϩ T cells ( ) and 5% more activated CD8 ϩ T cells ( P p .03 P p ) than participants without hepatitis C infection, after ad-.006 justment for other factors. Participants with frequent low-level viremia in the year before immunophenotyping (150% of plasma HIV RNA determinations were detectable (50-1000 copies/mL) had 5% more activated CD8 ϩ T cells than patients with sustained undetectable plasma HIV RNA levels ( ), P p .03 but similar levels of CD4 ϩ T cell activation (2% more; P p ) after adjustment for other factors. For each increase of 100 .14 cells/mm 3 in the nadir CD4 ϩ T cell count, there were 1% fewer activated CD4 ϩ T cells ( ) and 1.5% fewer activated P p .003 CD8 ϩ T cells ( ), after adjustment for other factors. P p .05
DISCUSSION
Although most HIV-infected patients experience sustained CD4
ϩ T cell gains while receiving virologically suppressive HAART, some patients never experience robust CD4 ϩ T cell gains [5] , and others fail to achieve a normal CD4 ϩ T cell count even after several years of therapy [3] . Because T cell activation is predictive of disease progression in the untreated patients [10, 11, 37] , even independent of virus load [12, 38] , we hypothesized that abnormal T cell activation might persist in patients experiencing long-term viral suppression and might be associated with the immunologic response to therapy. Among HIV-infected participants with a median of almost 2 years of HAART-mediated viral suppression, we found substantial levels of both CD4 ϩ and CD8 ϩ T cell activation, well above the levels observed in HIV-uninfected persons. Furthermore, higher levels of CD4 ϩ T cell activation were independently associated with lower CD4 ϩ T cell gains experienced in the first 3 months of therapy, and higher levels of CD8 ϩ T cell activation were independently associated with lower CD4 ϩ T cell gains after month 3. Our results provide further support for the hypothesis that T cell activation plays a critical role in HIV pathogenesis. It has long been proposed that T cell activation may be a mechanism by which HIV infection leads to CD4 ϩ T cell depletion. Given the small proportion of T cells that are actually infected by HIV [39] , it has been inferred that mechanisms other than direct loss of infected CD4 ϩ T cells must play a role in CD4 ϩ T cell depletion [30, [40] [41] [42] . Indeed, HIV infection activates uninfected, resting T cells either indirectly, via inflammatory cytokines [43, 44] , or directly, via contact with antigenpresenting cells presenting HIV antigens [18, 19, 45, 46] or exposure to gp120 and other viral factors [47] . These activated T cells undergo rapid proliferation [14] [15] [16] and are prone to spontaneous apoptosis [17, 41, 42] . Normally, some progeny of T cells activated by an antigenic stimulus revert back to longlived resting phenotypes after withdrawal of the activating stimulus. However, in the presence of ongoing antigen and inflammatory stimulation by HIV, the resting pool of naive and memory CD4 ϩ T cells may be continually drained, resulting in an inability to restore the CD4 ϩ T cells lost as a consequence of HIV infection [30] . This hypothesis is supported by the observation that sooty mangabeys, which fail to develop increased levels of T cell activation and apoptosis in response to simian immunodeficiency virus infection, rarely develop CD4 ϩ T cell depletion, despite ongoing CD4 ϩ T cell infection and destruction by simian immunodeficiency virus [48] . Our finding that increased CD8 ϩ T cell activation is associated with lower CD4 ϩ T cell gains after 3 months of HAARTmediated viral suppression is consistent with other work relating CD8 ϩ T cell activation to disease progression in untreated patients [10] [11] [12] 17] . Interestingly, these studies have generally concluded that markers of CD8 ϩ activation, but not CD4 ϩ activation, predict clinical progression, although there is some controversy on this point [38] . One possible explanation for the predictive superiority of CD8 ϩ T cell activation markers is related to differential rates of HIV infection observed in activated T cells. Because activated CD4 ϩ T cells are preferentially infected by HIV [19] [20] [21] [22] 49] , their half-lives are determined not only by the rate of activation-induced apoptosis but also by the rate of HIV infection and direct virus-mediated cell death [50] . Higher levels of HIV replication might reduce the percentage of activated CD4 ϩ T cells by accelerating their removal, and therefore CD8 ϩ T cell activation markers can be expected ϩ5 (3-7)
!.001
Each 10-year increase in age Ϫ37 (Ϫ88 to 13) .14 Ϫ50 (Ϫ90 to Ϫ7 NOTE. Factors associated with the change in CD4 ϩ T cell count from month 3 of HAART (or the date on which a plasma HIV RNA level р1000 copies/mL was achieved, if this occurred after month 3) to the date of immunophenotyping were assessed using linear regression. Adjusted regression coefficients are reported from a single multivariate model containing all of the listed factors. CI, confidence interval. a . 2 R p 0.55 b Duration of period before flow cytometry was done in which plasma HIV RNA levels were continuously р1000 copies/mL. c Percentage of all plasma HIV RNA measurements after the date of viral suppression that were detectable (50-1000 copies/ mL) for each participant.
to be more closely associated with the ability of HIV to cause generalized T cell activation and, by extension, the rate at which CD4 ϩ T cells are gained or lost.
It is also interesting that HIV-infected patients maintaining viral suppression in this study had substantially higher levels of T cell activation than did HIV-uninfected control subjects. This difference was observed even when HIV-infected participants with persistent detectable viremia or hepatitis C virus coinfection were excluded. Because the half-life of activated CD4 ϩ and CD8 ϩ T cells is short [50] , the presence of heightened T cell activation after years of suppressive HAART suggests the presence of ongoing antigenic stimulation. This might reflect ongoing low-level HIV replication in lymphoid tissues; the presence of other chronic infections, as a result of continued immunodeficiency (e.g., herpesvirus infections); or persistent immunologic dysregulation that is not reversed by HAART-mediated viral suppression. The former possibility is consistent with a recent study in which treatment intensification among patients with very low-level viremia (HIV RNA level, 2.5-50 copies/mL) resulted in decreased levels of plasma HIV RNA and decreased levels of T cell activation [51] . Although abnormal levels of T cell activation were observed in our participants, it is notable that the levels appeared to decrease as the duration of viral suppression increased. We did not perform repeated measurements over time and therefore cannot exclude the possibility that patients with high levels of persistent T cell activation were preferentially excluded from our sample because of virologic failure; however, the observed association was not confounded by the extent of low-level viremia and suggests that levels of CD8 ϩ T cell activation continue to decrease for years after viral suppression is achieved. This might reflect a continued, albeit gradual, decrease in the level of viral replication that remains below the level of detection of standard plasma HIV RNA assays and/or it might reflect the slow decay of the latent reservoir of infected cells. In either case, a slow decrease of CD8 ϩ T cell activation over time might ϩ T cell restoration in patients receiving virologically suppressive HAART [6] [7] [8] [9] . In our study, high levels of CD8 ϩ T cell activation, older age, and decreased levels of naive CD4 ϩ T cells were all independently associated with blunted late CD4 ϩ T cell gains. To the extent that age and the percentage of naive CD4 ϩ T cells are surrogates for thymic function when adjusting for levels of T cell activation, our data support a model in which 2 related but largely independent factors determine the CD4 ϩ T cell gains experienced by patients with HAART-mediated viral suppression: T cell activation and thymic function. A potential limitation of our study is the lack of pre-HAART and repeated during-HAART measurements of T cell activation. Because we only measured markers of T cell activation once and measured HAART-mediated CD4 ϩ T cell changes retrospectively, we cannot prove that high levels of T cell activation predict lower CD4 ϩ T cell gains. However, existing prospective data on untreated HIV-infected individuals [10] [11] [12] show that our interpretation of a causal relationship is plausible. Another potential limitation is the male predominance and high prevalence of protease inhibitor-based regimens in our cohort, which may limit the generalizability of our findings to other patient populations. Finally, we found several factors to be associated with persistent T cell activation, which suggest potential approaches to optimizing the immunologic responses to virologically suppressive HAART. First, we observed increased levels of CD8 ϩ T cell activation in participants with lower pre-HAART nadir CD4 ϩ T cell counts. This observation is consistent with a recent report of decreased responses to vaccination in HAART-treated patients with normal current CD4 ϩ T cell counts but low CD4 ϩ T cell nadirs [55] and suggests that initiating therapy earlier in untreated patients might be associated with improved immunologic function. However, because levels of CD8 ϩ T cell activation may decline even after several years of viral suppression, it is possible that the immunologic perturbations caused by delaying therapy may be reversible. Second, we observed increased CD8 ϩ T cell activation in participants with frequent low-level viremia. This suggests that further suppression of viral replication resulting from intensification of HAART may provide some marginal immunologic benefits, as has been observed in 2 recent studies [51, 56] . Third, hepatitis C virus coinfection was associated with persistent T cell activation, which confirms the conclusions of work published elsewhere [57] . This observation suggests that treatment of other chronic inflammatory diseases might improve immunologic responses to HAART. Fourth, because almost all of our participants had abnormal levels of CD8 ϩ T cell activation, treatment of T cell activation itself with immunomodulatory medications might be beneficial in HAART-treated patients with sustained viral suppression. In a recent trial, patients with early HIV infection who were treated with HAART plus 8 weeks of cyclosporin achieved and maintained much higher CD4 ϩ T cell counts and levels of HIVspecific immune responses than did patients treated with HAART alone [58] . Although trials of cyclosporin in chronically infected patients with varying degrees of viral suppression have failed to show benefit [59, 60] , future trials of immunomodulators may hold promise if they are targeted at chronically infected patients maintaining viral suppression. In summary, we have shown that abnormal levels of T cell activation exist in most patients experiencing long-term HAART-mediated viral suppression and that the extent of activation is associated with treatment-associated CD4 ϩ T cell gains. Improving our understanding of how HIV activates the immune system may lead to the development of more-specific adjuvants to HAART that reverse the immunologic perturbations caused by HIV infection.
